2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes

Type 2 diabetes is a major threat to human health in the 21st century. More than half a billion people may suffer from this pandemic disease in 2030, leading to a huge burden of cardiovascular complications. Recently, 2 novel antidiabetic agents, glucagon-like peptide 1 receptor agonists and sodium-...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Chern-En Chiang, MD, PhD, Kwo-Chang Ueng, MD, Ting-Hsing Chao, MD, Tsung-Hsien Lin, MD, PhD, Yih-Jer Wu, MD, PhD, Kang-Ling Wang, MD, Shih-Hsien Sung, MD, PhD, Hung-I Yeh, MD, PhD, Yi-Heng Li, MD, PhD, Ping-Yen Liu, MD, PhD, Kuan-Cheng Chang, MD, PhD, Kou-Gi Shyu, MD, PhD, Jin-Long Huang, MD, PhD, Cheng-Dao Tsai, MD, Huei-Fong Hung, MD, Ming-En Liu, MD, Tze-Fan Chao, MD, PhD, Shu-Meng Cheng, MD, PhD, Hao-Min Cheng, MD, PhD, Pao-Hsien Chu, MD, Wei-Hsian Yin, MD, PhD, Yen-Wen Wu, MD, PhD, Wen-Jone Chen, MD, PhD, Wen-Ter Lai, MD, Shing-Jong Lin, MD, PhD, San-Jou Yeh, MD, Juey-Jen Hwang, MD, PhD, Charles Jia-Yin Hou, MD
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2021-09-01
coleção:	JACC: Asia
Assuntos:	antidiabetic agents chronic kidney disease heart failure Taiwan Society of Cardiology type 2 diabetes
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2772374721000855
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!